Hot-selling Products
US$20.00-29.00 / vial
10 vial (MOQ)
US$30.00-46.00 / vial
10 vial (MOQ)
US$38.00-48.00 / vial
10 vial (MOQ)
US$38.00-48.00 / vial
10 vial (MOQ)
US$20.00-29.00 / vial
500 vial (MOQ)
US$38.00-48.00 / vial
10 vial (MOQ)
US$58,000.00-70,000.00 / kg
1 kg (MOQ)
Company Profile
Posseifill Biotech
Restore your natural grace
COMPANY PROFILE
Established in 2016, we pioneer end-to-end solutions for regenerative biomaterials, especially in the field of dermal filler, from R&D to commercial scale manufacturing. We are open to collaboration models including distribution, ODM/OEM, raw material customization, CDMO, technology transfer, and joint ventures.
Technology Breakthroughs
- Precision-Engineered Biomaterial Platforms
Through oxygen-free vacuum polymerization, we achieve 99.8% monomer conversion - the industry's highest yield - ensuring batch-to-batch consistency at kilogram-scale production. Advanced directional modification technology creates bespoke PLLA/PCL composites with tunable hydrophilicity, antimicrobial properties, and collagen-stimulating capabilities.
- Revolutionary ECM Bioengineering
We overcome critical limitations in regenerative biomaterials with CRISPR-edited, zero-immunogenicity ECM. Our enzymatic decellularization process preserves >95% of native collagen/elastin structures while eliminating immune risks.
- Microsphere Mastery for Natural Results
As pioneers in microfluidic manufacturing (China's first operational line), we produce perfectly uniform microspheres (30-80μ M ± 0.6 dispersity) at 90% yield - 4.5× Industry average.
Production & Capacity
Our Flagship GMP Facility (33, 000 sqm, Jiangsu, China):
- Dual Regulatory Compliance: Meets China NMPA + EU MDR/FDA standards.
- Expansive Scale: 5 dedicated workshops housing 9 advanced production lines.
- Unmatched Regenerative Biomaterials Output: Largest capacity in China, exceeding 10 million+ annual doses.
- Pioneering Technology: Home to China's first microfluidic production line.
10+ Years Deep domain expertise in regenerative biomaterials
20+ Products Class III dermal filler in pipeline
60+ Patents Core IP in polymer microspheres
Technology Breakthroughs
- Precision-Engineered Biomaterial Platforms
Through oxygen-free vacuum polymerization, we achieve 99.8% monomer conversion - the industry's highest yield - ensuring batch-to-batch consistency at kilogram-scale production. Advanced directional modification technology creates bespoke PLLA/PCL composites with tunable hydrophilicity, antimicrobial properties, and collagen-stimulating capabilities.
- Revolutionary ECM Bioengineering
We overcome critical limitations in regenerative biomaterials with CRISPR-edited, zero-immunogenicity ECM. Our enzymatic decellularization process preserves >95% of native collagen/elastin structures while eliminating immune risks.
- Microsphere Mastery for Natural Results
As pioneers in microfluidic manufacturing (China's first operational line), we produce perfectly uniform microspheres (30-80μ M ± 0.6 dispersity) at 90% yield - 4.5× Industry average.
Production & Capacity
Our Flagship GMP Facility (33, 000 sqm, Jiangsu, China):
- Dual Regulatory Compliance: Meets China NMPA + EU MDR/FDA standards.
- Expansive Scale: 5 dedicated workshops housing 9 advanced production lines.
- Unmatched Regenerative Biomaterials Output: Largest capacity in China, exceeding 10 million+ annual doses.
- Pioneering Technology: Home to China's first microfluidic production line.
10+ Years Deep domain expertise in regenerative biomaterials
20+ Products Class III dermal filler in pipeline
60+ Patents Core IP in polymer microspheres
Authentication
Business Type:
Manufacturer/Factory & Trading Company
Main Products:
Dermal Filler
,
Caha
,
Plla
,
Skin Booster
Year of Establishment:
2016-12-22
Number of Employees:
110
Management System Certification:
ISO9001:2015, Others
Address:
No. 20 Wenzhou Road, Shuyang County Economic Development Zone, Suqian City, Jiangsu Province
Solutions
OEM/ODM
Factory Tour
Sample Order
